Ulcerative Colitis Patients In England Get New Treatment Option
NICE Reverses Initial Rejection Of Janssen’s Stelara
Executive Summary
Stelara is a cost-effective use of National Health Service resources, but only where a TNF-alpha inhibitor has failed or cannot be used, and when the product is offered at the price reduction agreed with the health department’s commercial medicines arm, says the latest advice from England’s health technology assessment body, NICE. The move comes after a similar recommendation made earlier this month by NICE’s counterpart in Scotland.
You may also be interested in...
HTA: Scotland Says Yes To Stelara For Ulcerative Colitis
The decision by the Scottish Medicines Consortium contrasts with recent draft guidance from England’s health technology assessment body, NICE, that recommended against the National Health Service using the Janssen product for ulcerative colitis.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.